Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

Johnson & Johnson (NYSE:JNJ) and Legend Biotech (NASDAQ:LEGN) said a long-term study showed their cell therapy Carvykti ...

Data from the Phase 3 AURIGA study show Darzalex Faspro plus lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly increases MRD-negative conversion rates at ...

Johnson & Johnson reports positive results for Talvey in combination with Darzalex Faspro, pomalidomide and Tecvayli in the ...

Johnson & Johnson and Legend Biotech's CAR-T cell therapy Carvykti reduced the risk of death by 45% compared to standard of ...

Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...

HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

Today is European Myeloma Day, a date dedicated to raising awareness of key issues affecting myeloma patients across Europe. This year, Myeloma Patients Europe (MPE) is highlighting the role of ...